+
DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements
Technology

DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024.

With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.

Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.

Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.

Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.

Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024. With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing. Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility. Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development. Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible. Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

Next Story
Real Estate

No glass boxes!

India is moving away from the ‘glass box’ syndrome, all-glass façades that were widely used in commercial buildings in the last two decades but came at a significant environmental cost given the country’s predominantly hot and humid climate. Poor thermal performance, excessive heat gain and dependency on mechanical cooling systems made buildings with glass façades energy guzzlers and significantly increased their carbon footprint.That said, it’s important to be aware that “glass is not the enemy,” points out Heena Bhargava, Architect, Architecture Discipline. “How it ..

Next Story
Infrastructure Transport

Why do pavements fail?

India’s highways continue to expand at a healthy pace. But conversations on the surface quality of highways are growing louder because major deficiencies and black spots continue to be identified, and they are cause for concern.“Road surface roughness causes vehicle vibrations that, in turn, can affect the performance of drivers,” explains Dr V K Gahlot, Road Safety Auditor, Centre for Research and Sustainable Development (CfRSD). “Continuous exposure may induce fatigue, a contributory factor to road accidents. Road surface roughness also affects the vehicle operating cost...

Next Story
Infrastructure Urban

APAC Logistics Rents Fall for First Time Since 2020

Logistics rents across the Asia-Pacific region declined 0.4% year-on-year in H1 2025, marking the first annual drop since 2020, according to Knight Frank’s Logistics Highlights H1 2025 report. Despite global trade tensions and cautious occupier sentiment, India emerged as a standout performer, driven by robust manufacturing momentum and supply chain recalibration.Regional Trends and DivergenceWhile rents largely remained stable across most markets, regional differences became more pronounced:Mainland China continued to see rental declines, though the pace of decline moderated to 12.8% YoY, s..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?